top of page
Browse by category
Search
The Obesity Society commends FDA's resolution of obesity drug shortages and calls for enforcement against unauthorised compounding
The Obesity Society (TOS) has acknowledged the FDA’s recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and...
Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity
The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with...
Lilly's Zepbound (tirzepatide) achieved total mean weight loss of 26.0% from baseline to 88 weeks
Detailed results from SURMOUNT-4 have shown Zepbound (tirzepatide) injection achieved superior mean percent change in body weight...
Zepbound (tirzepatide) available in US pharmacies for adults living with obesity
Eli Lilly and Company has announced that Zepbound (tirzepatide) injection is now available in US pharmacies for adults with obesity (with...
FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management
The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...
Browse by tag
bottom of page